The Medical Letter on Drugs and Therapeutics
Spiriva Respimat - An Oral Inhalation Spray for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD),1 has now also been approved in an inhalation spray formulation (Spiriva Respimat – Boehringer Ingelheim). According to the manufacturer, the Respimat device improves delivery of tiotropium to the lungs because, unlike with the Handihaler, it is not dependent on the strength of the patient's breath intake.

MAINTENANCE TREATMENT – In patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator (an anticholinergic or a beta2-agonist) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. A combination of an anticholinergic and a beta2-agonist can be used for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Spiriva Respimat - An Oral Inhalation Spray for COPD
Article code: 1465e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian